Trial Profile
Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Alefacept (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Acronyms ITN T1DAL; T1DAL
- 16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association
- 11 Jun 2019 Results differentiating depletion and expansion of CD8+ T cell subsets in type 1 diabetes mellitus were presented at the 79th Annual Scientific Sessions of the American Diabetes Association.
- 18 May 2016 Results of a post hoc analysis of glycemic control data published in the Clinical Therapeutics